current issues in molecular biology

MDPI

Article

Generation of an Insecticidal Human Domain Antibody from a Phage Library Targeting *Plutella xylostella* Brush-Border Membrane Vesicles

Xiaodan Hu [1], Xiao Zhang [2], Junmin Fan [1], Wei Chen [2], Fang Ji [1], Qing Wang [1], Juanjuan Tian [1], Jinfeng Hou [1], Hong Wang [3], Shuting Yu [1], Wenwen Qi [1], Xianjin Liu [2,*], Yuan Liu [2,*] and Chunqin Xie [1]

[1] Department of Tea and Food Science, Jiangsu Vocational College of Agriculture and Forestry, Zhenjiang 212400, China; huxiaodanhappy@126.com (X.H.); xiechunqin@jsafc.edu.cn (C.X.)
[2] Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Institute of Food Safety and Nutrition, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, China
[3] School of Pharmaceutical Engineering, Zhejiang Pharmaceutical University, Ningbo 315207, China
* Correspondence: jaasliu@jaas.ac.cn (X.L.); liuyuan@jaas.ac.cn (Y.L.)

Abstract

The importance of protein-based materials in agricultural pest control has received increasing attention in recent years. Herein, *Plutella xylostella* brush-border membrane vesicles (BBMVs) were used as a target to screen for human domain antibodies with insecticidal activity. Three rounds of panning of the phage display library yielded the domain antibody C4D, which competed with the Cry1Ac toxin to bind to *P. xylostella* BBMVs. Against *P. xylostella* larvae, the recombinant soluble C4D protein showed an LC_{50} of 1.57 μg/cm^2 (95% fiducial limits: 0.83–2.54). Using pull-down assays and liquid chromatography–tandem mass spectrometry, we identified the C4D binding partner in *P. xylostella* midgut BBMVs to be a cadherin-like protein. Bio-Layer Interferometry assay revealed that the dissociation constant between soluble C4D and *P. xylostella* cadherin-like protein was 2.99 × 10^{-6} M. Thus, the present study explored strategies to generate insecticidal antibodies, and the human domain antibody C4D identified and characterized in this study can serve as a framework for generating novel insecticidal agents.

Keywords: domain antibody; insecticidal protein; BBMVs; phage display

Check for updates

Received: 8 January 2026
Revised: 1 February 2026
Accepted: 4 February 2026
Published: 8 February 2026

Copyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.

1. Introduction

The diamondback moth *Plutella xylostella* (L.) (*Lepidoptera*: *Plutellidae*) is a destructive global lepidopteran pest [1]. The larvae of *P. xylostella*, equipped with chewing mouthparts, are voracious feeders that cause substantial damage to economically important cruciferous crops, including cabbage, cauliflower, broccoli, Brussels sprouts, Chinese cabbage, and Chinese kale [2,3]. Globally, annual economic losses due to *P. xylostella* amount to an estimated $4–5 billion [4]. Controlling the population of *P. xylostella* is challenging because of its remarkable environmental adaptability, high fecundity, and short generation time. The intensive, long-term use of chemical pesticides against *P. xylostella* has led to its resistance to 97 distinct chemical compounds, rendering it one of the most resistant insect species globally [5,6]. Therefore, alternative, eco-friendly control strategies are urgently needed.

Currently, *Bacillus thuringiensis* (Bt) and its insecticidal genes represent one of the most successful biotechnological tools in Integrated Pest Management, being both formulated

into microbial insecticides and widely utilized in the development of transgenic insect-resistant crops. The wide application of Bt crystal proteins, known as Cry toxins, in pest management has led to a drastic reduction in insecticide use alongside significant economic, environmental, and social benefits [7,8]. The success of Cry toxins in pest control has established proteins as potential insecticidal agents. As per the immune network theory, specific antibodies (anti-idiotypic antibodies) can mimic the structure and function and act as copies of some antigens, including proteins, polypeptides, small molecules, and other substances [9,10]. Such specific antibodies have been widely used in biomedical applications, such as disease diagnosis, disease treatment, and vaccine development [11,12]. Given the broad and diverse functional capabilities of antibodies, such as in medicine and biotechnology, it can be hypothesized that certain antibodies exhibit insecticidal activity similar to that shown by Cry toxins. Single-domain antibodies (nanobodies) are the smallest antibody fragments with binding functionality [13]. They are considered a class of next-generation antibodies owing to their small size (approximately 2.5 × 4 nm), high tissue penetration capability, high conformational stability, and ease of production and engineering [14,15]. Moreover, human-derived antibodies exhibit lower immunogenicity than antibodies derived from other sources, such as mice, llamas, or rabbits, eliciting reduced immune responses in humans—a characteristic that enhances their safety profile as pesticides [13]. As insecticidal agents, human domain antibodies may offer distinct advantages: a safer profile from low human immunogenicity, ease of engineering due to their stable, simple structure, and scalable production. These advantages suggest that they represent a compelling novel strategy for environmentally friendly pest control.

Although the specific mechanism underlying the insecticidal activity of Cry proteins remains elusive, the general understanding is that they interact with receptor proteins in the brush-border membrane vesicles (BBMVs) of the insect midgut, ultimately inducing insect mortality [8,16,17]. Researchers have demonstrated marked enhancement in the insecticidal activity of Cry toxins by replacing some structural loops with peptides that can bind to BBMVs [18–20]. One of the primary mechanisms underlying insect resistance to Cry toxins involves alterations in the binding affinity of receptors on insect BBMVs to activated Bt toxins [21–24]. Given the integral role of the insect midgut in digestion and nutrient absorption, BBMVs represent a promising target for insecticide development.

Phage display technology, which was awarded the Nobel Prize in Chemistry in 2018, serves as a powerful and versatile method, allowing for the discovery of proteins with both high affinity and specificity [25]. It is based on the in vitro selection of peptides or proteins displayed as fusion proteins on the surface of a bacteriophage [26]. In addition to its extensive use in several clinical and therapeutic applications, this technology is increasingly being used in the fields of food safety and pest control [27–29].

In the present study, *P. xylostella* BBMVs were used as antigens to screen for human domain antibodies with insecticidal activity. After three rounds of panning, an antibody called C4D was isolated from a human domain antibody library. C4D was found to compete with Cry1Ac toxin for binding to *P. xylostella* BBMVs. C4D was recombinantly expressed in *Escherichia coli* BL21 (DE3) cells, and the insecticidal activity of soluble C4D against *P. xylostella* was demonstrated through bioassays. The specific BBMVs protein targeted by C4D was isolated using a pull-down assay and identified using liquid chromatography–tandem mass spectrometry (LC–MS/MS) as *P. xylostella* cadherin-like protein.

2. Materials and Methods

2.1. Amplification of Phage Human Domain Antibodies and Extraction of Brush-Border Membrane Vesicles

The domain antibody library, obtained from the Medical Research Council HGMP Resource Center, contains 3×10^9 phages, with each phage displaying a different antibody fragment fused to its terminal phage geneIII protein. The domain antibodies were derived from a single human VH framework (V3–23/D47), with diversity introduced only in the antigen-binding site, which comprises complementarity-determining region 1 (CDR1), CDR2, and CDR3. The phage antibody repertoire of the naive domain antibody library was produced by infecting the stocked *E. coli* TG1 library with KM13 helper phages following a standard protocol [30].

A total of 500 fourth-instar *P. xylostella* larvae of the HN strain, starved for 3 h, were aseptically dissected under a microscope and immediately subjected to a wash with ice-cold 150 mM NaCl solution. The midguts were transferred to a sterile homogenizer containing 3 mL of homogenization buffer (300 mM mannitol, 5 mM EGTA, 17 mM Tris, pH 7.5), homogenized for 30 s, and incubated on ice for 30 s. This cycle was repeated six times until no visible tissue fragments remained. The resulting homogenate was transferred to a 50 mL centrifuge tube. Subsequently, an equal volume of ice-cold 24 mM $MgCl_2$ solution was added. The mixture was incubated on ice for 30 min, followed by centrifugation at 3500× *g* for 15 min at 4 °C. The supernatant was carefully collected in a new microcentrifuge tube and centrifuged at 30,000× *g* for 1 h at 4 °C. The pellet was carefully isolated and resuspended in 500 µL of HEPES buffer (10 mM HEPES, 130 mM KCl, 10% glycerol, pH 7.4). The resultant BBMVs' suspension was aliquoted and stored at −80 °C.

2.2. Human Domain Antibody Library Panning and Identification of Domain Antibodies Targeting P. xylostella BBMVs

To enrich the specific domain antibodies targeting *P. xylostella* BBMVs, the rescued phage domain antibody library was subjected to panning (Figure 1). Briefly, a well of a high-protein-binding plate was coated with 1 mL of a 100 µg/mL BBMVs solution prepared in phosphate-buffered saline (PBS; 0.2 g KCl, 3.6 g Na_2HPO_4,8 g NaCl, and 0.24 g KH_2PO_4 dissolved in 1 L of deionized water, pH 7.4) overnight at 4 °C. The next day, the well was subjected to four washes with 5 mL of PBS, and the unoccupied sites were blocked with 3 mL of PBS containing 5% (*w*/*v*) skim milk (MPBS) at 37 °C for 2 h. The well was washed four times again with PBS, followed by the addition of the phage domain antibody library, which contained 2.3×10^{11} phages in 1 mL of 5% (*w*/*v*) MPBS. The plate was gently agitated at 100 rpm for 1 h and allowed to stand for another 1 h at 25 °C. The phages were removed. The well was first washed ten times with 5 mL of PBST (PBS with 0.1% Tween-20). This was followed by two additional washes with 5 mL of PBS. Unbound or weakly bound phage particles were first washed away. Subsequently, the remaining bound phages were eluted by incubation with 1 mL of 150 µg/mL trypsin protease (Invitrogen, Carlsbad, CA, USA) for 1 h at room temperature with gentle agitation at 100 rpm. Eluted phages were mixed with log-phase *E. coli* TG1 cultures and incubated for 1 h at 37 °C. For isolation of *E. coli* TG1 clones harboring antibody genes, the mixture was plated on tryptone-yeast extract plates containing 100 µg/mL ampicillin. The clones obtained were used to titer the output phage and amplify phage antibodies for the next round of panning. In the next two rounds of panning, trypsin was replaced with 200 µg/mL Cry1Ac toxins to elute the specific binders, and a reduced BBMV coating concentration and more stringent washing steps were implemented to enhance the enrichment of high-affinity binders. The second round of panning featured a 50 µg/mL solution of BBMVs and 15 washes with PBST, while the third round featured a 25 µg/mL solution of BBMVs and 20 washes with PBST.




Figure 1. Schematic of the panning process for selecting BBMVs-targeted human domain antibodies. The procedure consisted of the following key steps: (1–2) Pre-clearance by removing phages binding to 5% (*w*/*v*) MPBS; (3–4) Washing to remove non-specifically bound phages; (5) Elution of phages specifically bound to BBMVs; (6) Amplification of the eluted phage pool for subsequent rounds of selection or analysis.

2.3. Phage Enzyme-Linked Immunosorbent Assay

The polyclonal phages obtained after each round of panning were tested by phage enzyme-linked immunosorbent assay (ELISA). The output phages of each round were amplified, and 1×10^9 phages were added to wells that had been coated with 100 µL of 30 µg/mL BBMVs in 5% (*w*/*v*) solution and blocked with 300 µL of 5% (*w*/*v*) MPBS. After being incubated at 37 °C for 1 h, the wells were subjected to four washes with PBST. To detect bound phages, 100 µL of horseradish peroxidase (HRP)-conjugated anti-M13 monoclonal antibody (1:3000; Sino Biological Inc., Beijing, China) was added to the wells and incubated at 37 °C for 1 h. After washing the wells four times with PBST, 100 µL of 3,3′,5,5′-tetramethylbenzidine substrate (GenScript, Piscataway, NJ, USA) was added to each well and incubated at 37 °C for 15 min. The reaction was stopped by adding 50 µL of 2 M sulfuric acid. Subsequently, the absorbance at 450 nm was recorded using a UV-Vis plate reader. Wells coated with 5% (*w*/*v*) MPBS were defined as the negative control. The phage pools with the highest absorbance values were chosen for monoclonal phage ELISA. Three independent dilution processes were performed, with phages from each process assayed in technical triplicate.

Following random selection, individual clones from the output library were rescued with KM13 helper phage. The produced monoclonal phage antibodies were then analyzed by ELISA against BBMVs. The protocol for monoclonal phage ELISA was the same as that for polyclonal phage ELISA. Clones with specific BBMVs binding were selected for further analysis. Three independent rescue processes were performed, with phages from each process assayed in technical triplicate.

Antibodies showing the highest enrichment and strongest binding to BBMVs were selected for competitive ELISA, which was performed in the same manner as monoclonal phage ELISA, except that the monoclonal phages were incubated with 100 µg/mL Cry1Ac. Three independent rescue processes were performed, with phages from each process assayed in technical triplicate.

The ELISA results were analyzed by one-way ANOVA followed by Tukey's multiple comparisons test, using GraphPad Prism 10. Data are from three independent experiments (n = 3).

2.4. Expression and Purification of Soluble C4D

To analyze the insecticidal activity of human domain antibody C4D, soluble C4D protein was expressed using a prokaryotic expression system. The coding sequence of human domain antibody C4D was subjected to amplification with the primers C4D-F (5′-CATG*CCATGG*CCCAGGTGCAGCTGTTGGAGTCTG-3′), which contained a *Nco*I site (italicized), and C4D-R (5′-ATAAGAAT*GCGGCCGC*CAGATCCTCTTCAGAGATGAGT TTCTGCTCGCTCGAGACGGTGAC-3′), which contained a *Not*I site (italicized) and a c-Myc label. The amplicon was cloned into pET26b (+) vector (Novagen, Madison, WI, USA), and the recombinant plasmid was transformed into *E. coli* BL21 (DE3) cells (TransGen Biotech, Beijing, China) to express soluble C4D protein. Following induction with 0.5 mM isopropyl β-D-thiogalactopyranoside (IPTG; Invitrogen, Carlsbad, CA, USA), the bacterial culture was cultivated for 16 h at 25 °C with agitation (220 rpm). The induced cells were harvested and lysed by sonication. Following centrifugation of the lysates, the clarified supernatants were subjected to purification using a nickel–nitrilotriacetic acid (Ni-NTA) affinity column (GE Healthcare, Piscataway, NJ, USA) to isolate soluble C4D. The purified protein was desalted using a desalting column (GE Healthcare, Piscataway, NJ, USA). The concentration of purified C4D was measured using a Nanodrop spectrophotometer. Subsequently, the protein was aliquoted and stored at −80 °C.

2.5. Insect Bioassays

For insect bioassays, plastic Petri dishes (6 cm in diameter) were coated with insect diet. Each insect diet was overlaid with 1 mL of C4D protein solution (at varying concentrations in PBS) to achieve final concentrations of 0.4, 0.8, 1.6, 3.2, 6.4 or 12.8 μg/cm^2 and was then allowed to air-dry. For each treatment, five plates (replicates) were prepared, with 20 s-instar *P. xylostella* larvae of the HN strain were placed on each dried diet surface, resulting in a total of 100 larvae per treatment. The D3H clone, which was obtained from the same human domain antibody library panning but showed no competitive activity with Cry1Ac, and PBS were used as negative control. A series of concentrations of Cry1Ac toxin was used as the positive control. Mortality was assessed after 5 days, and larvae that failed to pupate were also recorded as dead. The concentration of proteins that kills 50% of the larvae (LC_{50}) was calculated using GraphPad Prism 10 software.

2.6. Pull-Down Assays

The *P. xylostella* midgut BBMVs proteins interacting with C4D were captured through pull-down assays performed using Dynabeads™ His-Tag isolation and pull-down beads (Invitrogen, Carlsbad, CA, USA). Briefly, 50 μL of a resuspension of Dynabeads™ magnetic beads was transferred to a microcentrifuge tube. After a brief (2 min) magnetic separation, the supernatant was aspirated and discarded. Next, 700 μL of 1.5 mg/mL soluble C4D protein dissolved in 1 × binding/wash buffer (300 mM NaCl, 50 mM sodium phosphate, 0.01% Tween-20, pH 8.0) was added to the beads and mixed well. The tube was subjected to incubation for 15 min at 25 °C on a roller, and then placed on a magnet for 2 min, following which the supernatant was discarded. The beads underwent four washes, each using 300 μL of 1 × Binding/Wash Buffer, and the supernatant was discarded after every wash. Next, 700 μL of 1 mg/mL BBMVs dissolved in 1 × pull-down buffer (3.25 mM sodium phosphate, 70 mM NaCl, 0.0% Tween-20, pH 7.4) was added to the beads. The tube was incubated on a roller for 30 min at 4 °C and then placed on a magnet for 2 min, following which the supernatant was discarded. After washing the beads four times with 300 μL

of 1 × Binding/Wash Buffer and discarding the supernatant, 50 µL of His-elution buffer (300 mM imidazole, 50 mM sodium phosphate, 300 mM NaCl, 0.01% Tween-20, pH 8.0) was added to the tube. The tube was placed on a roller for 5 min at 4 °C. The beads were collected using a magnet, and the supernatant—containing the interaction partner of C4D—was transferred to a fresh tube. The beads not incubated with C4D served as a control. The isolated protein was first analyzed using sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE). The protein band was excised from the gel and further analyzed via LC–MS/MS. The analysis was performed on a Thermo Fisher Q Exactive Plus system equipped with a Nano Flex ion source operating in data-dependent acquisition mode. The raw mass spectrometry data were processed using Proteome Discoverer 2.5 software and subsequently searched against the UniProt *Plutella xylostella* database with a false discovery rate (FDR) threshold set to <1% at all identification levels.

2.7. Bio-Layer Interferometry Assay (BLI)

The binding between soluble C4D and *P. xylostella* cadherin-like fragment (amino acids T1202 to I1447) was analyzed by BLI using the Octet RED96e system (Sartorius, Goettingen, Germany). *Plutella xylostella* cadherin-like fragment was first expressed recombinantly in our laboratory [31]. The BLI was performed using aminopropylsilane (APS)-coated biosensor tips (Sartorius Goettingen, Germany). First, tips were immersed in a solution containing *P. xylostella* cadherin-like fragment at a concentration of 20 µg/mL for 3 min to allow for immobilization. Following this, the tips were immersed in kinetic buffer (PBS supplemented with 0.1% (*w*/*v*) bovine serum albumin, BSA) for 30 s. For affinity measurement, soluble C4D was serially diluted in kinetic buffer to a series of concentrations (1 µM, 0.5 µM, 0.25 µM, 0.125 µM), which were then applied to the immobilized tips to monitor binding interactions. All binding signals were recorded using the Octet System Data Acquisition software (version 9.0, Sartorius, Goettingen, Germany). The soluble D3H was used as negative control.

3. Results

3.1. Enrichment of Domain Antibodies Binding to Brush-Border Membrane Vesicles

The magnitude of enrichment can be estimated by calculating the proportion of input phages that bind to BBMVs. The input phage number for each round of panning was maintained at 10^{11}, while the relative proportion of output phage increased from the first to the third round, confirming the successful enrichment of domain antibodies targeting BBMVs (Table 1).

Table 1. Recovery of phages during selection against BBMVs.

Selection Round	Input [a]	Output [a,b]	Phage Bound [c]
1	2.3×10^{11}	1.2×10^{4}	5.2×10^{-8}
2	2.0×10^{11}	1.2×10^{5}	6.0×10^{-7}
3	1.5×10^{11}	1.9×10^{7}	1.3×10^{-4}

[a] Phage inputs and outputs were calculated by transduction to *E. coli* TG1. [b] Number of eluted phages expressed as colony-forming unit per milliliter (cfu/mL). [c] Phage bound = output/input.

3.2. ELISA Analysis of Phage Display Screening

Phages that became amplified after each round of selection were diluted to 1×10^{10} colony-forming units/mL and subjected to polyclonal phage ELISA. The absorbance for BBMVs binding increased significantly with each panning round, with the signal after the third round being significantly higher than after the first ($p < 0.0001$) and second rounds ($p < 0.0001$), as shown in Figure 2A. In contrast, the binding signal to

the MPBS control remained low and was significantly lower (p = 0.0021) than that of the naïve phage library (Figure 2A). These results indicate the successive enrichment of BBMVs-specific binders.




Figure 2. ELISA analysis of phage display screening. (**A**) ELISA analysis of polyclonal phages rescued after each round of screening. (**B**) Monoclonal phage ELISA analysis of third-round output clones. Each clone was rescued with KM13 helper phage and adjusted to an equivalent titer prior to analysis. (**C**) The competition was observed in the presence of 100 μg/mL Cry1Ac. Differences in ELISA results were assessed by one-way ANOVA followed by Tukey's multiple comparisons test, using GraphPad Prism 10. The data are presented as the mean values ± SD. Different letters indicate significant differences between groups at $p < 0.05$. (n = 3).

A total of 380 individual clones were randomly selected from the output of the third round of panning and subjected to monoclonal ELISA against BBMVs. MPBS served as a control. Clones with ELISA signals at least 3-fold higher in intensity than the control were selected as positive binders to BBMVs. As a result, 32 positive clones were selected and sequenced.

Sequencing results revealed several identical antibody sequences. We selected the six most frequently occurring sequences for subsequent experiments. The representative strains corresponding to each sequence were A5E, A7C, B4C, C4D, D2F, and D3H, and the number of clones with identical amino acid sequences as these strains was 3, 6, 5, 5, 3, and 4, respectively. The results of monoclonal ELISA are shown in Figure 2B.

The six representative clones selected from monoclonal phage ELISA were subjected to competitive ELISA to assess whether they competed with Cry1Ac toxin in binding to BBMVs. Competitive ELISA (Figure 2C) revealed that among the six domain antibodies tested, only the binding of C4D to BBMVs was significantly inhibited by Cry1Ac toxin, decreasing by 45.95% (from 0.75 ± 0.02 to 0.40 ± 0.02; $p < 0.0001$). In contrast, the binding of the other five antibodies was not significantly affected (all $p > 0.05$).

3.3. Expression and Purification of Soluble C4D

The recombinant *E. coli* BL21 (DE3) clone was sequenced to verify the correct insertion of the C4D antibody gene into pET-26b (+) vector. The expression of soluble C4D protein was verified by SDS–PAGE and Western blotting (Figure 3). The amino acid sequence of human domain antibody C4D is presented in Figure 3A. *E. coli* BL21 (DE3) cells harboring empty pET-26b (+) vector and induced at the same time were used as a control. The

results of SDS–PAGE analysis showed that *E. coli* BL21 (DE3) cells harboring the C4D coding sequence exhibited a specific protein band at approximately 15 kDa (Figure 3B), the same position at which a sharp band was observed when the purified protein was run on SDS–PAGE. Given that C4D was expressed with a c-Myc fusion tag, the purified soluble C4D protein was detected by Western blotting with an HRP-conjugated c-Myc antibody (GenScript, Piscataway, NJ, USA). The Western blotting results showed a specific band at the same position as the band on SDS–PAGE, and the molecular weight was consistent with that of soluble C4D (Figure 3C). These results verified the successful expression and purification of soluble C4D, and SDS-PAGE analysis also demonstrated high purity of the recombinant C4D protein (Figure 3B). The purified protein was obtained at a yield of approximately 1.5 mg/mL in PBS and stored at −80 °C.




Figure 3. Expression and analysis of the soluble human domain antibody C4D. (**A**) Amino acid sequence of human domain antibody C4D and D3H. Lane M, protein marker; Lane 1, *E. coli* BL21 (DE3) harboring empty vector; Lane 2, Purified soluble C4D protein; Lane 3, *E. coli* BL21 (DE3) harboring pET-26b (+)-C4D. (**B**) Analysis of C4D expression by SDS-PAGE. (**C**) Western blotting analysis of soluble C4D expression with c-Myc antibodies.

3.4. Insect Bioassay

In the insect bioassays, the LC_{50} of Cry1Ac was 6.60 ng/cm^2 (95% fiducial limit: 6.10–7.14), suggesting these insects were sensitive to Cry1Ac and could be used for bioassays. The results of the insect bioassay revealed the LC_{50} of C4D was 1.57 μg/cm^2 (95% fiducial limit: 0.83–2.54), whereas no mortality was observed in the D3H group at the concentration of 20 μg/cm^2, confirming the insecticidal activity of C4D antibody (Table 2).

Table 2. Toxicity of the tested proteins against *P. xylostella*.

Treatment	LC_{50} (95% Fiducial Limits) (ng/cm^2)	R^2	HillSlope	Degrees of Freedom
Cry1Ac	6.60 (6.10–7.14)	0.99	−1.41	3
C4D	1.57 (0.83–2.54) × 10^3	0.87	−0.52	5
D3H	>20,000 [a]			

[a] *Plutella xylostella* showed no mortality at the maximum concentration tested (20,000 ng/cm^2).

3.5. Pull-Down Assays

The protein isolated through pull-down assays was first analyzed by SDS–PAGE. Compared with the control, the pull-down sample displayed a specific band at approximately 180 kDa (Figure 4A). The band was excised, trypsin-digested, and analyzed by LC–MS/MS (Figure 4B). The analysis identified the target protein as the *P. xylostella* cadherin-like protein (GenBank: AAS98023.1). Under stringent filtering criteria, this identification was supported by 197 high-confidence peptide-spectrum matches (PSMs), corresponding to 26 unique peptides and yielding a sequence coverage of 13%. The mass spectrum of one peptide is shown in Figure 5B. *Plutella xylostella* cadherin-like protein was previously reported to be a protein present in *P. xylostella* BBMVs, functioning as a Cry1Ac receptor [31].




Figure 4. Pull-down assay identifying C4D-binding proteins from *P. xylostella* BBMVs. (**A**) SDS-PAGE of eluted proteins. Lane M: Marker; Lane 1: Beads + BBMVs (control); Lane 2: Beads + C4D + BBMVs. (**B**) Representative LC-MS/MS spectrum confirming *P. xylostella* cadherin-like protein. The peptide sequence [R].IVSDISESFKVDAEKNIISLTR.[E] was matched to *P. xylostella* cadherin-like protein. Peaks correspond to fragment ions, with m/z and relative intensity shown on the x- and y-axes, respectively.




Figure 5. BLI analysis of human domain antibodies binding to the *P. xylostella* cadherin-like fragment. (**A**) BLI analysis of different antibodies binding to the *P. xylostella* cadherin-like fragment. (**B**) BLI analysis of C4D binding to the *P. xylostella* cadherin-like fragment. The binding affinity was measured using an Octet RED96e system.

3.6. Binding Activity Analysis of Soluble C4D Protein with P. xylostella Cadherin-like Fragment

BLI analysis was performed to assess binding. The results revealed that while C4D could bind to the *P. xylostella* cadherin-like fragment, D3H showed no binding activity (Figure 5A). BLI analysis demonstrated a concentration-dependent increase in the binding response of soluble C4D to the *P. xylostella* cadherin-like fragment, confirming their specific interaction. The measured binding affinity (K_D) was 2.99 × 10^{-6} M, with an association rate constant (K_a) of 1.28 × 10^3 $M^{-1}s^{-1}$and a dissociation rate constant (K_b) of 3.83 × 10^{-3} s^{-1} (Figure 5B).

4. Discussion

Bt toxins, which have been successfully formulated into microbial insecticides and engineered into transgenic crops, represent a cornerstone of modern insect control and are the most extensively studied insecticidal proteins to date. According to the commonly accepted mechanism, Cry toxins exert their insecticidal activity by binding to receptors on the surface of BBMVs in the insect midgut [8,16,32]. Shao et al. demonstrated a 9-fold increase in the toxicity of Cry1Ab toward the brown planthopper *Nilaparvata lugens* by replacing the domain II loops of the toxin with BBMVs-binding peptides [19]. Similarly, Chougule et al. enhanced the toxicity of Cyt2Aa toward the pea aphid *Acyrthosiphon pisum* and the green peach aphid *Myzus persicae* by replacing one loop of the toxin with BBMVs-binding peptides [33]. Given the integral role of the insect midgut in digestion and nutrient absorption, BBMVs represent a promising target for insecticide development. Phage display technology is an efficient, high-throughput method for high-affinity and high-specificity antibody discovery. During panning, antigen-specific competitive elution is an efficient strategy to facilitate target antibody isolation, proving advantageous for the production of anti-idiotypic antibody fragments [34]. To maximize the isolation of human domain antibodies with insecticidal activity against *P. xylostella*, we conducted competitive panning of phage-displayed libraries on BBMVs substrates using Cry1Ac as the displacement eluent. In Round 1 of screening, trypsin elution was employed to maximize recovery of all BBMVs-bound antibodies, followed by amplification to expand the population for subsequent selection—a strategy that prevented the loss of binding clones under stringent initial conditions. Polyclonal analysis confirmed that BBMVs-binding antibodies were effectively enriched after Round 1. In Round 2, competitive elution was performed with Cry1Ac toxin, and no significant increase was noted post-Round 2 compared with Round 1. This was potentially due to the displacement of antibodies binding to BBMVs sites not targeted by Cry1Ac. Competitive screening further enriched target-specific antibodies in Round 3, in alignment with the planned selection strategy. The predominance of noncompetitively eluted antibodies after screening may be a result of the high fluid shear stress generated during microfluidic washing, causing the dissociation of lower-affinity antibodies against BBMVs.

Panning of the human antibody library yielded the insecticidal domain antibody C4D, which competed with the Cry1Ac toxin to bind to *P. xylostella* BBMVs. The pull-down assays, LC–MS/MS, and BLI analysis identified and verified the C4D binding partner in *P. xylostella* midgut BBMVs to be midgut cadherin-like protein. In invertebrates, cadherin-like protein belongs to a major family of calcium-dependent transmembrane glycoproteins. Their critical functions encompass the regulation of cell migration, intercellular adhesion, tissue organization, and morphogenesis [35]. Cadherin-like proteins also engage in signal transduction. Their ectodomain mediates interactions with other adhesion molecules, and their cytoplasmic domain connects to specific intracellular proteins, facilitating downstream signaling [36]. Current research on insect midgut cadherin-like proteins primarily focuses on their role in the mode of action of Cry toxins. Although Cry toxins target multiple

receptors and their precise mechanism of toxicity remains unclear, cadherin-like proteins in various insect species have been confirmed as one of the functional receptors for Cry toxins [37–39]. Gao et al. investigated the binding of Cry toxin to *P. xylostella* cadherin-like protein and the subsequent cellular toxicity, concluding that *P. xylostella* cadherin-like protein might function as a Cry1Ac receptor [31]. Crucially, in one of the widely accepted insecticidal mechanisms of Cry1A toxins, insect cadherin-like protein can activate an intracellular death-signaling pathway analogous to that of GPCRs. Owing to this functional homology coupled with structural similarities, some researchers classified it within the cadherin-GPCR family [40,41]. GPCRs have long been established as valuable targets in human drug discovery and are now also considered for pest management. In recent years, insect GPCRs have emerged as particularly promising targets for next-generation pesticides. Their high species specificity further offers the potential for selective pest control with minimal off-target effects [42]. Therefore, our findings demonstrate a correlation between C4D binding to cadherin-like proteins and larval mortality, but do not elucidate the downstream toxicological mechanism. The precise mechanism by which this binding leads to death remains speculative and constitutes an important objective for future investigation.

In the present research, we obtained a human domain antibody, C4D, with insecticidal activity. Xie et al. previously reported an antibody called GEAb-dVL, consisting of two light chains, that demonstrated insecticidal activity against *P. xylostella* larvae [43]. Lin et al. identified a single-chain variable fragment antibody called M4 that induced mortality against *P. xylostella* larvae [44]. All these studies confirm that insecticidal activity can be attributed to some specific antibodies. However, when quantitatively benchmarked against established toxins, the current efficacy of such antibody-based agents remains substantially lower. The Cry1Ac toxin, for example, exhibits an LC_{50} of 6.6 ng/cm^2 against *P. xylostella*. In comparison, the human single-domain antibody C4D reported here has an LC_{50} of approximately 1.57 μg/cm^2–about 240-fold higher than that of Cry1Ac. This gap in potency is further contextualized by other antibody formats: GEAb-dVL shows an LC_{50} of 235 μg/cm^2, and M4 induces only 27.8% mortality at 53 μg/cm^2 [43,44]. Therefore, while C4D represents the most active human antibody-derived scaffold identified in our study, its activity level clearly positions it as a proof-of-concept molecule rather than a field-ready biopesticide. These results highlight that the primary value of C4D is in demonstrating the feasibility of engineering human domain antibodies for insecticidal function. This represents a foundational step toward designing future biocontrol agents with improved efficacy and modularity for pest management. In Cry toxins, the α-helical conformation is central to the pore-forming ability of the toxin, and hence, to its toxicity. Surprisingly, antibodies lacking this secondary structure element retained their insecticidal activity. Previous studies have implicated the surface-exposed loops of Cry toxins in receptor interactions [45]. Interestingly, antibodies interact with specific antigens through CDRs on the apex [46]. In addition to their similarity in position and role in interacting with binding partners, both Cry toxin loops and CDRs of antibodies display marked diversity in their sequence composition, length, and structural conformations [46,47]. These functional and structural similarities between Cry toxin loops and CDRs of antibodies may be the reason why antibodies can show insecticidal activity. The human domain antibody C4D obtained in this study exhibited approximately 240-fold higher LC_{50} than Cry1Ac against *P. xylostella* larvae, probably because of its low binding affinity to *P. xylostella* cadherin-like protein and its simple structure compared with Cry1Ac. Our future research will aim to enhance the binding affinity of C4D for cadherin-like protein through antibody evolution and reinforce structural stability through multimerization engineering, thereby boosting insecticidal activity.

5. Conclusions

Herein, *P. xylostella* BBMVs were used as a target to screen for human domain antibodies with insecticidal activity. After three rounds of panning, we isolated C4D, a human domain antibody that could compete with Cry1Ac toxin to bind to *P. xylostella* BBMVs. Recombinant soluble C4D was expressed in *E. coli* BL21 (DE3) cells, and bioassays were performed to validate the insecticidal activity of soluble C4D against *P. xylostella*. The specific binding partner of C4D was isolated using pull-down assays and identified using LC–MS/MS as *P. xylostella* cadherin-like protein, a functional Cry toxin receptor. The binding between soluble C4D and *P. xylostella* cadherin-like protein was verified through BLI analysis. Thus, the present study explored strategies to generate insecticidal antibodies, laying the groundwork for the generation of new insecticidal agents.

Author Contributions: Conceptualization, X.H. and X.L.; methodology, X.H. and X.Z.; software, J.F.; validation, F.J., S.Y. and W.Q.; formal analysis, H.W. and J.H.; investigation, X.H., W.C., Q.W. and J.T.; resources, X.H. and Y.L.; data curation, X.Z.; writing—original draft preparation, X.H.; writing—review and editing, X.H., Y.L. and X.Z.; supervision, C.X. and X.L.; project administration, C.X.; funding acquisition, X.H., X.L. and F.J. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by General Program of Natural Science Foundation of Jiangsu Provincial Institutions of Higher Education (24KJB210010), Scientific Research Startup Fund for High-Level Talents of Jiangsu Vocational College of Agriculture and Forestry (2024rc39), Jiangsu Province Agricultural Science and Technology Independent Innovation Fund [CX(22)1009], General Program of Jiangsu Provincial Natural Science Foundation (BK20231248) and Science and Technology Project for Social Development of Jurong (ZA42316).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author(s).

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:

Bt	*Bacillus thuringiensis*
BBMVs	Brush-border membrane vesicles
LC–MS/MS	Liquid chromatography–tandem mass spectrometry
CDR	Complementarity-determining region
PBS	Phosphate-buffered saline
MPBS	Skim milk dissolved in phosphate-buffered saline
PBST	Phosphate-buffered saline containing 0.1% Tween-20
ELISA	Enzyme-linked immunosorbent assay
HRP	Horseradish peroxidase
SDS–PAGE	Sodium dodecyl sulfate–polyacrylamide gel electrophoresis

References

1. Jamtsho, T.; Banu, N.; Kinley, C. Critical review on past, present and future scope of diamondback moth management. *Plant Arch.* **2021**, *21*, 1199–1210. [CrossRef]
2. Li, Y.P.; Xiao, D.U.; Liu, F.F.; Yin, L.I.; Liu, T.X. Ultrastructure of the sensilla on antennae and mouthparts of larval and adult *Plutella xylostella* (Lepidoptera: Plutellidae). *J. Integr. Agr.* **2018**, *17*, 1409–1420. [CrossRef]
3. Saleh, H.M.M.; Dey, D.; Tomar, B.S. The hymenopterous parasitoids of the diamondback moth, *Plutella xylostella* (L.) (Lepidoptera: Plutellidae), on cruciferous vegetables in Delhi, India. *Egypt. J. Biol. Pest. Co.* **2023**, *33*, 93. [CrossRef]

4. Que, X.Y.; Fu, F.M.; Yang, G.R.; Lei, B.F.; Ali, A. A positively charged carbon dot complex improves the bioactivity of Isaria fumosorosea against *Plutella xylostella* (Linnaeus). *Chem. Biol. Technol. Ag.* **2024**, *11*, 192. [CrossRef]
5. Shen, J.; Li, Z.; Li, D.; Wang, R.; Zhang, S.; You, H.; Li, J. Biochemical mechanisms, cross-resistance and stability of resistance to metaflumizone in *Plutella xylostella*. *Insects* **2020**, *11*, 311. [CrossRef]
6. Xia, X.; Sun, B.; Gurr, G.M.; Vasseur, L.; Xue, M.; You, M. Gut microbiota mediate insecticide resistance in the diamondback moth, *Plutella xylostella* (L.). *Front. Microbiol.* **2018**, *9*, 25. [CrossRef] [PubMed]
7. Wu, K.; Lu, Y.H.; Feng, H.; Jiang, Y.; Zhao, J.Z. Suppression of cotton bollworm in multiple crops in China in areas with Bt toxin-containing cotton. *Science* **2008**, *321*, 1676–1678. [CrossRef]
8. Bravo, A.; Likitvivatanavong, S.; Gill, S.S.; Soberón, M. Bacillus thuringiensis: A story of a successful bioinsecticide. *Insect Biochem. Mol. Biol.* **2011**, *41*, 423–431. [CrossRef] [PubMed]
9. Jerne, N.K. Towards a network theory of the immune system. *Ann. Immunol.* **1974**, *125C*, 373–389.
10. Kılıç, G.; Demirkan, E.; Yücel, F. Development of anti-idiotypic monoclonal antibody mimicking SARS-CoV-2 receptor binding domain. *Mol. Biotechnol.* **2025**, *67*, 1556–1564. [CrossRef]
11. Vázquez, A.M.; Hernández, A.M.; Macías, A.; Montero, E.; Gómez, D.E.; Alonso, D.F.; Gabri, M.R.; Gómez, R.E. Racotumomab: An anti-idiotype vaccine related to N-glycolyl-containing gangliosides-preclinical and clinical data. *Front. Oncol.* **2012**, *2*, 150. [CrossRef]
12. Segatori, V.I.; Vazquez, A.M.; Gomez, D.E.; Gabri, M.R.; Alonso, D.F. Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. *Front. Oncol.* **2012**, *2*, 160. [CrossRef]
13. Khodabakhsh, F.; Behdani, M.; Rami, A.; Kazemi-Lomedasht, F. Single-domain antibodies or nanobodies: A class of next-generation antibodies. *Int. Rev. Immunol.* **2018**, *37*, 316–322. [CrossRef]
14. Shoemaker, R.L.; Larsen, R.J.; Larsen, P.A. Single-domain antibodies and aptamers drive new opportunities for neurodegenerative disease research. *Front. Immunol.* **2024**, *15*, 1426656. [CrossRef] [PubMed]
15. Xu, C.; Liu, X.; Zhang, C.; Zhang, X.; Zhong, J.; Liu, Y.; Hu, X.; Lin, M.; Liu, X. Establishment of a sensitive time-resolved fluoroimmunoassay for detection of *Bacillus thuringiensis* Cry1Ie toxin based nanobody from a phage display library. *Anal. Biochem.* **2017**, *518*, 53–59. [CrossRef] [PubMed]
16. Sanahuja, G.; Banakar, R.; Twyman, R.M.; Capell, T.; Christou, P. *Bacillus thuringiensis*: A century of research, development and commercial applications. *Plant Biotechnol. J.* **2011**, *9*, 283–300. [CrossRef]
17. Zhang, X.; Candas, M.; Griko, N.B.; Taussig, R.; Bulla, L.A., Jr. A mechanism of cell death involving an adenylyl cyclase/PKA signaling pathway is induced by the Cry1Ab toxin of *Bacillus thuringiensis*. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 9897–9902. [CrossRef]
18. Wu, S.J.; Koller, C.N.; Miller, D.L.; Bauer, L.S.; Dean, D.H. Enhanced toxicity of *Bacillus thuringiensis* Cry3A delta-endotoxin in coleopterans by mutagenesis in a receptor binding loop. *FEBS. Lett.* **2000**, *473*, 227–232. [CrossRef]
19. Shao, E.; Lin, L.; Chen, C.; Chen, H.; Zhuang, H.; Wu, S.; Sha, L.; Guan, X.; Huang, Z. Loop replacements with gut-binding peptides in Cry1Ab domain II enhanced toxicity against the brown planthopper, *Nilaparvata lugens* (Stål). *Sci. Rep.* **2016**, *6*, 20106. [CrossRef] [PubMed]
20. Ishikawa, H.; Hoshino, Y.; Motoki, Y.; Kawahara, T.; Kitajima, M.; Kitami, M.; Watanabe, A.; Bravo, A.; Soberon, M.; Honda, A.; et al. A system for the directed evolution of the insecticidal protein from *Bacillus thuringiensis*. *Mol. Biotechnol.* **2007**, *36*, 90–101. [CrossRef]
21. Wu, Y. Detection and mechanisms of resistance evolved in insects to cry toxins from *Bacillus thuringiensis*. *Adv. Insect Physiol.* **2014**, *47*, 297–342. [CrossRef]
22. Xu, X.; Wu, Y. Disruption of Ha_BtR alters binding of *Bacillus thuringiensis* delta-endotoxin Cry1Ac to midgut BBMVs of *Helicoverpa armigera*. *J. Invertebr. Pathol.* **2008**, *97*, 27–32. [CrossRef] [PubMed]
23. Van Rie, J.; Mcgaughey, W.H.; Johnson, D.E.; Barnett, B.D.; Van Mellaert, H. Mechanism of insect resistance to the microbial insecticide *Bacillus thuringiensis*. *Science* **1990**, *247*, 72–74. [CrossRef]
24. Arenas, I.; Bravo, A.; Soberón, M.; Gómez, I. Role of alkaline phosphatase from Manduca sexta in the mechanism of action of *Bacillus thuringiensis* Cry1Ab toxin. *J. Biol. Chem.* **2010**, *285*, 12497–12503. [CrossRef]
25. Smith, G.P. Phage display: Simple evolution in a petri dish (Nobel lecture). *Angew. Chem. Int. Ed. Engl.* **2019**, *58*, 14428–14437. [CrossRef]
26. Bronte-Moreno, O.; González-Barcala, F.J.; Muñoz-Gall, X.; Pueyo-Bastida, A.; Ramos-González, J.; Urrutia-Landa, I. Impact of air pollution on asthma: A scoping review. *Open Respir. Arch.* **2023**, *5*, 100229. [CrossRef]
27. Pardo-López, L.; Soberón, M.; Bravo, A. *Bacillus thuringiensis* insecticidal three-domain Cry toxins: Mode of action, insect resistance and consequences for crop protection. *FEMS. Microbiol. Rev.* **2013**, *37*, 3–22. [CrossRef] [PubMed]

28. Mishra, R.; Guo, Y.; Kumar, P.; Cantón, P.E.; Tavares, C.S.; Banerjee, R.; Kuwar, S.; Bonning, B.C. Streamlined phage display library protocols for identification of insect gut binding peptides highlight peptide specificity. *Curr. Res. Insect Sci.* **2021**, *1*, 100012. [CrossRef] [PubMed]
29. Choi, M.Y.; Vander Meer, R.K. GPCR-Based bioactive peptide screening using phage-displayed peptides and an insect cell system for insecticide discovery. *Biomolecules* **2021**, *11*, 583. [CrossRef]
30. Lee, C.M.; Iorno, N.; Sierro, F.; Christ, D. Selection of human antibody fragments by phage display. *Nat. Protoc.* **2007**, *2*, 3001–3008. [CrossRef]
31. Gao, M.; Dong, S.; Hu, X.; Zhang, X.; Liu, Y.; Zhong, J.; Lu, L.; Wang, Y.; Chen, L.; Liu, X. Roles of Midgut Cadherin from two moths in different *Bacillus thuringiensis* action mechanisms: Correlation among toxin binding, cellular toxicity, and synergism. *J. Agric. Food Chem.* **2019**, *67*, 13237–13246. [CrossRef] [PubMed]
32. Khairullin, R.M.; Sorokan, A.V.; Gabdrakhmanova, V.F.; Maksimov, I.V. The perspective properties and directions of *Bacillus thuringiensis* use for plant protection. *Appl. Microbiol. Biotechnol.* **2023**, *59*, 408–424. [CrossRef]
33. Chougule, N.P.; Li, H.; Liu, S.; Linz, L.B.; Narva, K.E.; Meade, T.; Bonning, B.C. Retargeting of the *Bacillus thuringiensis* toxin Cyt2Aa against hemipteran insect pests. *Proc. Nat. Acad. Sci. USA* **2013**, *110*, 8465–8470. [CrossRef]
34. Goletz, S.; Christensen, P.A.; Kristensen, P.; Blohm, D.; Tomlinson, I.; Winter, G.; Karsten, U. Selection of large diversities of antiidiotypic antibody fragments by phage display. *J. Mol. Biol.* **2002**, *315*, 1087–1097. [CrossRef]
35. Gumbiner, B.M. Cell adhesion: The molecular basis of tissue architecture and morphogenesis. *Cell* **1996**, *84*, 345–357. [CrossRef]
36. Dorsch, J.A.; Candas, M.; Griko, N.B.; Maaty, W.S.; Midboe, E.G.; Vadlamudi, R.K.; Bulla, L.A., Jr. Cry1A toxins of *Bacillus thuringiensis* bind specifically to a region adjacent to the membrane-proximal extracellular domain of BT-R(1) in Manduca sexta: Involvement of a cadherin in the entomopathogenicity of *Bacillus thuringiensis*. *Insect Biochem. Mol. Biol.* **2002**, *32*, 1025–1036. [CrossRef]
37. Ibrahim, M.A.; Griko, N.B.; Bulla, L.A., Jr. Cytotoxicity of the *Bacillus thuringiensis* Cry4B toxin is mediated by the cadherin receptor BT-R_3 of Anopheles gambiae. *Exp. Biol. Med. Maywood* **2013**, *238*, 755–764. [CrossRef]
38. Morin, S.; Biggs, R.W.; Sisterson, M.S.; Shriver, L.; Ellers-Kirk, C.; Higginson, D.; Holley, D.; Gahan, L.J.; Heckel, D.G.; Carrière, Y.; et al. Three cadherin alleles associated with resistance to *Bacillus thuringiensis* in pink bollworm. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 5004–5009. [CrossRef]
39. Zhang, H.; Yu, S.; Shi, Y.; Yang, Y.; Fabrick, J.A.; Wu, Y. Intra- and extracellular domains of the *Helicoverpa armigera* cadherin mediate Cry1Ac cytotoxicity. *Insect Biochem. Mol. Biol.* **2017**, *86*, 41–49. [CrossRef]
40. Liu, L.; Boyd, S.D.; Bulla, L.A., Jr.; Winkler, D.D. The defined toxin-binding region of the cadherin G-protein coupled receptor, BTR1, for the active Cry1Ab toxin of Bacillus thuringiensis. *J. Proteonomics Bioinf.* **2018**, *11*, 201–210. [CrossRef]
41. Ibrahim, M.A.; Griko, N.; Junker, M.; Bulla, L.A. *Bacillus thuringiensis*: A genomics and proteomics perspective. *Bioeng. Bugs.* **2010**, *1*, 31–50. [CrossRef] [PubMed] [PubMed Central]
42. Birgül Iyison, N.; Shahraki, A.; Kahveci, K.; Düzgün, M.B.; Gün, G. Are insect GPCRs ideal next-generation pesticides: Opportunities and challenges. *FEBS. J.* **2021**, *288*, 2727–2745. [CrossRef]
43. Xie, Y.; Xu, C.; Gao, M.; Zhang, X.; Lu, L.; Hu, X.; Chen, W.; Jurat-Fuentes, J.L.; Zhu, Q.; Liu, Y.; et al. Docking-based generation of antibodies mimicking Cry1A/1B protein binding sites as potential insecticidal agents against diamondback moth (*Plutella xylostella*). *Pest. Manag. Sci.* **2021**, *77*, 4593–4606. [CrossRef]
44. Lin, M.; Liu, Y.; Shen, C.; Meng, M.; Zhang, X.; Xu, C.; Jin, J.; Hu, X.; Zhu, Q.; Xie, Y.; et al. Generation of anti-idiotypic antibodies mimicking Cry2Aa toxin from an immunized mouse phage display library as potential insecticidal agents against *Plutella xylostella*. *Biochem. Biophys. Res. Commun.* **2024**, *691*, 149308. [CrossRef]
45. Deist, B.R.; Rausch, M.A.; Fernandez-Luna, M.T.; Adang, M.J.; Bonning, B.C. Bt toxin modification for enhanced efficacy. *Toxins* **2014**, *6*, 3005–3027. [CrossRef]
46. Li, J.D.; Carroll, J.; Ellar, D.J. Crystal structure of insecticidal delta-endotoxin from *Bacillus thuringiensis* at 2.5 A resolution. *Nature.* **1991**, *353*, 815–821. [CrossRef] [PubMed]
47. Wong, W.K.; Leem, J.; Deane, C.M. Comparative analysis of the CDR loops of antigen receptors. *Front. Immunol.* **2019**, *10*, 2454. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.